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Abstract
Introduction: The aim of this study was to measure serum sex hormone binding globulin (SHBG) profile in Chinese peri-menopausal 
women, and assess its correlation with insulin resistance (IR)-related parameter, namely HOMA-IR, in this special population. 
Material and methods: A cross-sectional study by the method of cluster sampling was performed in 1,827 women, who were in hospital 
for routine check-up. Serum SHBG profile and anthropometric indices of hormonal, adiposity, and metabolic variables were measured. 
According to their age and menstruation status, the subjects were divided into three groups: pre-menopause group, peri-menopause 
group, and post-menopause group. 
Results: Serum SHBG level was found to be negatively correlated with BMI in all groups and to increase in parallel with age in women of 
reproductive age. However, independently of age, it significantly increased from the onset of menopause transition, and slightly declined 
after menopause. After adjustment for age and BMI, HOMA-IR in peri-menopausal women was closely related only to SHBG. SHBG 
level was found to be the only independent significant determinant of HOMA-IR. On the basis of ROC curve analysis for the prediction 
of insulin resistance using HOMA-IR value, AUC for SHBG reached a value of 0.816 (0.636–0.996, 95% confidence interval). The best cut-
off value that discriminates peri-menopausal women with or without insulin resistance is 41.73 nmol/L, with a sensitivity of 81.4% and 
a specificity of 87.5%. 
Conclusions: Low SHBG level may be an independent risk factor of insulin resistance in Chinese peri-menopausal women. 
(Endokrynol Pol 2013; 64 (3): 197–202)
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Streszczenie
Wstęp: Celem badania było oznaczenie profilu stężeń globuliny wiążącej hormony płciowe (SHBG) w surowicy u Chinek będących 
w okresie okołomenopauzalnym oraz ocena korelacji tego profilu z parametrem insulinooporności HOMA-IR w tej szczególnej populacji.
Materiał i metody: Przeprowadzono badanie przekrojowe metodą doboru grupowego z udziałem 1827 kobiet przebywających w 
szpitalu na rutynowych badaniach kontrolnych. Oznaczono profil stężeń SHBG i parametry statusu hormonalnego, parametry otyłości 
i parametry metaboliczne. Uczestniczki badania podzielono ze względu na wiek i status menstruacyjny na trzy grupy: grupę w okresie 
przedmenopauzalnym, grupę w okresie okołomenopauzalnym i grupę w okresie pomenopauzalnym.
Wyniki: Stwierdzono, że stężenie SHBG w surowicy wykazuje ujemną korelację z BMI we wszystkich grupach i wzrasta z wiekiem 
kobiet w wieku reprodukcyjnym. Stężenie SHBG ulegało też, niezależnie od wieku, znamiennemu wzrostowi od początku zmian me-
nopauzalnych, a następnie, po menopauzie, ulegało nieznacznemu zmniejszeniu. Po wzięciu poprawek na wiek i BMI, stwierdzono, że 
HOMA-IR u kobiet w okresie okołomenopauzalnym wykazuje ścisły związek wyłącznie z SHBG. Stwierdzono, że stężenie SHBG jest 
jedynym niezależnym istotnym determinantem HOMA-IR. Na podstawie analizy krzywej ROC dla predykcji insulinooporności na pod-
stawie wartości HOMA-IR stwierdzono, że AUC dla SHBG osiąga wartość 0,816 (95% przedział ufności: 0,636–0,996). W przypadku kobiet 
w okresie okołomenopauzalnym najlepszą wartość odcięcia odróżniającą kobiety z insulinoopornością od kobiet bez insulinooporności 
jest 41,73 nmol/l przy czułości wynoszącej 81,4% i swoistości wynoszącej 87,5%.
Wnioski: U Chinek w okresie okołomenopauzalnym niskie stężenie SHBG może stanowić niezależny czynnik ryzyka insulinooporności. 
(Endokrynol Pol 2013; 64 (3): 197–202)
Słowa kluczowe: globulina wiążąca hormony płciowe (SHBG), okres okołomenopauzalny, insulinooporność, wartość predykcyjna
Introduction
Peri-menopause and early post-menopause represent 
a critical period characterised by altered ovarian func-
tion, presenting as gradual and fluctuating decline of 
sex steroids, mostly oestradiol, synthesised and secreted 
by the ovaries [1]. Loss of ovarian oestrogen produc-
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the consequences of menopause, including oestrogen 
deficiency symptoms such as hot flushes, insomnia, 
depression and dyspareunia. Actually, the negative al-
terations of metabolic processes, latent inside the body, 
are not as provoking and prominent as the common 
complaints mentioned above, while the subsequent 
sequelae predispose this special population at high 
risk of developing long-term consequences, such as 
cardiovascular disease (CVD) and osteoporosis [2, 3]. 
Despite limited understanding of the exact mechanism 
by which oestrogen deficiency leads to increased CVD 
risks, several reports have revealed the effects of oestro-
gen deficiency on body fat distribution and excess body 
fat, and consequently insulin resistance (IR), which then 
increases the risk of dyslipidemia, inflammation, altered 
coagulation, and atherosclerosis [4–6]. Although IR can 
possibly be a result of physiological change directly due 
to ageing, it has been more noted as the central aetio-
logical factor of all CVD-correlated metabolic disorders, 
whether in relation to menopause or not [7]. 
Sex hormone-binding globulin (SHBG) is a circulating 
glycoprotein involved in transporting testosterone and 
oestradiol, modulating their serum concentrations in bio-
logical active format and influencing their bioavailability. It 
is mainly synthesised in the liver and binds testosterone with 
high affinity and oestrogens with lower affinity. Previous 
studies have demonstrated oestrogens as a promoting fac-
tor, and testosterone as an inhibiting factor, of the synthesis 
and blood levels of SHBG [8, 9]. Moreover, insulin has been 
shown to be an important inhibiting regulator of SHBG syn-
thesis in vivo and in vitro, and to block the stimulatory effect 
of 17b-oestradiol and T4 on SHBG [9]. Considering its close 
relationship with sex steroids, SHBG has been studied in the 
population of both pre-menopausal and post-menopausal 
women [2, 10], showing the association between SHBG and 
IR. In addition, SHBG may have biological actions beyond 
simply binding circulating sex hormones, which may impact 
on IR [11]. 
Given the paucity of relevant literature reported in 
mainland China, in the present study SHBG concen-
trations were determined in Chinese peri-menopausal 
women defined by the criteria of the Stages of Repro-
ductive Ageing Workshop (STRAW), and as well those 
within pre-menopause and post-menopause who were 
recruited as controls. Also, the relationship between 
SHBG levels and an IR-related parameter, namely 
HOMA-IR, was evaluated. 
Material and methods
Subjects
This cross-sectional study was carried out by the 
method of cluster sampling on 1,827 adult women 
aged 18 to 89 years referred to our hospital for routine 
check-up in 2009 and 2010. None of the women studied 
had known cardiovascular disease, thyroid disease, 
neoplasms, chronic renal failure, chronic hepatopathy 
or a history of ovarectomy. Furthermore, no women 
had been on any medications within the previous three 
months, including oral contraceptives; glucocorticoids; 
ovulation induction agents; antidiabetic and antiobesity 
drugs; or oestrogenic, antiandrogenic, or antihyper-
tensive medication; or drugs known to interfere with 
carbohydrate metabolism. The presence of medical 
conditions was assessed through self-report. Thyroid 
status was evaluated by free T3 (fT3), free T4 (fT4) and 
thyrotrophin (TSH) levels.
The menopausal status of each subject was defined 
according to the criteria of the Stages of Reproductive 
Ageing Workshop (STRAW) based on the retrospective 
menstrual calendars [12]. Women reporting a regular 
menstrual cycle were classified as pre-menopausal; peri-
menopause was defined as regular menstrual cycles 
but with duration changes of seven days or more, and 
as amenorrhoea for less than 12 months once during 
a year; having 12 consecutive amenorrhoea with no 
other causes was defined as post-menopause. In ad-
dition, we determined follicle stimulating hormone 
(FSH) and oestradiol (E2) blood levels as supplementary 
indicators of menopausal status, as previously sug-
gested [13]. After providing written informed consent, 
all participants had blood taken in the fasted state, and 
essential anthropometric parameters (height, weight, 
waist and hip circumference) were measured.
Anthropometric measurements
All study participants underwent classic anthropomet-
ric parameters measurements (height, weight, waist and 
hip circumference), carried out three times by a single 
tester. The average of two measurements of blood pres-
sure (BP) with the subject in the sitting position was 
taken at 5 min intervals after resting for at least 15 min. 
Height and weight were measured in light clothing 
without shoes. Body height was measured by a statom-
eter and body weight by a digital electronic weighing 
scale. Body mass index (BMI) was calculated as weight 
in kilograms divided by the square of height in metres. 
Waist circumferences were measured using a flexible 
measuring tape, midway between the xiphoid and the 
umbilicus during the mid-inspiratory phase. Hip cir-
cumference was obtained as the widest circumference 
at the level of the buttocks.
Biochemical and hormonal analysis 
After an overnight fast, blood samples were collected 
between 08:00 and 10:00 a.m. Samples were stored at 
−80°C and measured, as previously described [14], 
within six months.
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Sex hormone binding globulin (SHBG) was measured 
by enzyme-linked immunosorbent assay (ELISA). Intra- 
and inter-assay coefficients of variation of SHBG were 
< 6% and < 12% respectively. Testosterone, FSH, and E2 
were measured by chemiluminescence (ACS180 SE, Bayer, 
Germany). Fasting venous blood samples were also used to 
measure the levels of glucose, insulin, TC, TG, and HDL-
C. Plasma glucose was measured by the glucose oxidase 
method (Hitachi 7600) and plasma insulin was measured 
using a chemiluminescence immunometric assay and com-
mercial kit (Immulite 2000 Analyser; CPC). TC, HDL-C, and 
TG were measured using an enzymatic calorimetric method 
with the 7600 autoanalyser (Hitachi 7600). The LDL cho-
lesterol level was calculated using Friedewald’s equation. 
Homeostasis model assessment (HOMA) was applied to 
estimate the degree of IR. The equation used to obtain this 
value was as follows: HOMA-IR  =  [fasting plasma glucose 
(mmol/L)*insulin (μU/mL)]/22.5. Subjects were defined as 
having IR if their HOMA-IR values were higher than the 
95th percentile of HOMA-IR in all participants as a whole.
Statistical analyses 
Statistical analysis was carried out with SPSS 11.0 (SPSS, 
Chicago, IL, USA). The normal distribution of all studied 
parameters was checked with histograms and the Kolmog-
orov- Smirnoff test. After testing, all serum values showed 
normal distribution. Comparisons between groups were 
made with Student’s t-test. Pearson correlation coefficients 
were calculated to determine the correlations between 
various parameters. SHBG was used as diagnostic pa-
rameter. Multiple regression analyses were performed 
in the peri-menopausal women, including HOMA-IR as 
the dependent variable and the other clinical, hormonal 
and metabolic parameters as independent variables. ROC 
analysis was performed to examine its diagnostic test 
performance, i.e. the ability to distinguish women with 
and without IR. Sensitivity against (1 – specificity) was 
plotted at each level, and the area under the curve (AUC) 
— which reflects the probability of correctly identifying 
women with normal or abnormal insulin sensitivity. The 
Youden index (sensitivity + specificity – 1) was calculated 
to determine the best compromise between sensitivity 
and specificity; the closer the value is to 1, the greater the 
diagnostic power. Two-tailed p < 0.05 was considered 
statistically significant.
Results
According to the STRAW criteria described above, 
our cohort consisted of 1,249 pre-menopausal, 
239 peri-menopausal, and 339 post-menopausal wom-
en. Clinical and biochemical data is set out in Table I. 
Table I. Comparisons of clinical and biochemical characteristics in three study groups







Age (years) 30.09 ± 8.16 48.88 ± 3.42* 56.80 ± 5.01*, **
BMI [kg/m2] 21.49 ± 7.21 23.33 ± 3.15* 23.26 ± 3.34* 
WC [cm] 73.08 ± 8.31 82.28 ± 8.44* 82.53 ± 8.15* 
WHR 0.81 ± 0.06 0.85 ± 0.05* 0.86 ± 0.06*, **
SBP [mm Hg] 111.77 ± 12.75 118.94 ± 15.56* 123.12 ± 17.75*, **
DBP [mm Hg] 72.30 ± 9.08 78.00 ± 9.80* 78.90 ± 10.20* 
FPG [mmol/L] 5.25 ± 0.70 5.14 ± 0.82 5.38 ± 0.99*, **
FIN [μU/mL] 6.08 ± 23.13 7.01 ± 7.57 7.09 ± 4.63
HOMA-IR 1.43 ± 5.37 1.66 ± 2.20 1.75 ± 1.40
T [nmol/L] 1.79 ± 1.14 0.96 ± 0.52* 0.91 ± 0.88* 
SHBG [nmol/L] 61.72 ± 30.09 70.03 ± 39.27* 66.15 ± 37.56
Log FAI 0.61 ± 0.24 0.40 ± 0.22* 0.39 ± 0.25* 
TG [mmol/L] 1.11 ± 0.86 1.63 ± 1.54* 1.78 ± 1.17*, **
HDL-C [mmol/L] 1.49 ± 0.37 1.58 ± 0.38* 1.56 ± 0.38* 
LDL-C [mmol/L] 2.63 ± 2.14 3.27 ± 0.85 3.43 ± 0.90
TC [mmol/L] 5.49 ± 18.19 5.40 ± 1.09 5.77 ± 0.98
Data is presented as mean ± SD. WC — waist circumference; WHR — waist to hip circumference ratio; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; FPG — fasting plasma glucose; FIN — fasting plasma insulin; HOMA-IR — homeostasis model assessment-insulin resistance; T — total testosterone; 
SHBG — sex hormone binding globulin; FAI — free androgen index; TG — triglycerides; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density 
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As disclosed by ANOVA analysis, most anthropometric 
parameters, including WC, WHR, SBP, DBP, FPG, FIN, 
HOMA-IR and TG, were different among groups, with 
a trend toward an increase passing from pre- to peri- 
and post-menopause, though some of the differences 
did not reach statistically significant levels between two 
groups. With regard to SHBG, independently of age, it 
significantly increased from onset of menopause transi-
tion, and slightly declined after menopause. 
HOMA-IR showed no correlation with age or BMI 
in pre-menopausal women, a positive correlation (r = 
= 0.260, P = 0.043) with BMI, and no correlation with 
age in peri-menopausal women, and positive correlations 
with both age (r = 0.154, P = 0.040) and BMI (r = 0.435, 
P = 0.037) in post-menopausal women. 
SHBG was found to be significantly negatively cor-
related with BMI in all three groups [r = –0.074 (P = 
= 0.047), r = –0.364 (P = 0.032) and r = –0.204 (P = 0.038) 
respectively], and to be significantly positively correlated 
with age only in the pre-menopausal group (r = 0.105, 
P = 0.042). After adjusting for age and BMI, HOMA-IR 
in peri-menopausal women was closely related only 
to SHBG (Table II). Multiple regression analyses were 
performed in the peri-menopausal women, including 
HOMA-IR as the dependent variable and the other 
clinical, hormonal and metabolic parameters as inde-
pendent variables. As a result, SHBG level was found 
to be the only independent significant determinant of 
HOMA-IR. 
The diagnostic value of SHBG for predicting IR was 
tested by the ROC curve. As displayed in Table III and 
Figure 1, AUC for SHBG only in the peri-menopausal 
group reached a value of 0.816 (0.636–0.996, 95% confi-
dence interval) and the difference reached a statistically 
significant level. Several threshold values of serum 
SHBG level were analysed in terms of specificity and 
sensitivity from the ROC curve data. The best cut-off 
value that discriminates peri-menopausal women 
with or without insulin resistance is 41.73nmol/L, with 
a sensitivity of 81.4% and a specificity of 87.5%.
Discussion
The lower incidence of ischaemic heart diseases and 
thromboembolic diseases in women before menopause 
compared to men of the same age is well established 
[15, 16], while the gender advantage disappears after 
menopause, which over recent decades has been in-
terpreted primarily as reflecting oestrogen-mediated 
protection against atherosclerosis, indicating that 
female hormones participate in their modulation [17, 
18]. Thus, previous studies have paid more attention 
to the impact of oestrogen deficiency from the onset 
of menopause on the pathogenesis of cardiovascular 
Table II. Pearson’s correlation between SHBG and HOMA-IR and other relevant parameters after adjustment for age and 
BMI in three study groups
Tabela II. Korelacja Pearsona między SHBG i HOMA-IR oraz innymi istotnymi parametrami po wzięciu poprawki na wiek 
i BMI w trzech badanych grupach














WC –0.234 0.000 –0.115 NS –0.011 NS 0.032 NS 0.109 NS 0.146 0.008
WHR –0.185 0.000 –0.096 NS –0.043 NS 0.018 NS 0.054 NS 0.032 NS
SBP –0.110 0.000 –0.022 NS –0.043 NS 0.011 NS 0.047 NS 0.119 0.030
DBP –0.062 0.035 –0.006 NS –0.007 NS 0.034 NS 0.122 NS 0.088 NS
FPG –0.009 NS –0.109 NS –0.120 0.029 — — — — — —
FIN 0.002 NS –0.178 0.007 –0.162 0.003 — — — — — —
HOMA-IR 0.001 NS –0.164 0.013 –0.157 0.004 — — — — — —
SHBG — — — — — — 0.001 NS –0.164 0.013 –0.157 0.004
T –0.027 NS 0.062 NS –0.004 NS –0.008 NS –0.055 NS 0.140 0.011
FAI –0.335 0.000 –0.482 0.000 –0.338 0.000 –0.010 NS –0.063 NS 0.173 0.001
TG –0.140 0.000 –0.195 0.003 –0.181 0.001 0.020 NS 0.096 NS 0.296 0.000
HDL 0.041 NS 0.185 0.005 0.168 0.002 –0.045 NS –0.116 NS –0.175 0.001
LDL –0.082 0.005 –0.021 NS 0.056 NS –0.008 NS 0.046 NS 0.100 NS
TC –0.026 NS –0.005 NS 0.054 NS –0.005 NS 0.019 NS 0.113 0.039
P values < 0.05 are in bold; PRM-group — pre-menopause group; PEM-group — peri-menopause group; POM-group — post-menopause group; NS: not statistically 
significant
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and cerebrovascular diseases, while the pathogenic 
effect of abnormal androgen metabolism or oestrogen 
to androgen ratio imbalance has been little studied. 
As the major carrier of sex steroids in human plasma, 
SHBG influences the bioactivity of testosterone and 
oestradiol, and is regulated by their feedback control 
at the same time, indicating its important role in the 
maintenance of relative balance of oestrogen and an-
drogen after menopause. Found in patients with diverse 
metabolism-related disorders, IR was considered a com-
mon risk factor and could exist for several years prior 
to a confirmed diagnosis of these diseases. Insulin has 
been shown to be an important inhibiting regulator of 
SHBG synthesis in vivo and in vitro, and to block the 
stimulatory effect of 17b-oestradiol and T4 on SHBG 
[9]. Low SHBG level appears to be a biologic marker 
for IR [19]. Therefore, we mainly aimed at investigating 
the relationship between SHBG, IR-related parameter, 
namely HOMA-IR, and other anthropometric measure-
ments, and the value of SHBG profile in the prediction 
of IR in women of different ages, in order to provide 
supporting data for preventing and treating IR-related 
diseases among peri- and post-menopausal women. 
In accordance with previous studies [4, 20], various de-
grees of parallel change in BMI, waist circumference and 
WHR with ageing were found in this study, and the physi-
cal shape of women gradually changed to central adiposity 
with the tendency of HOMA-IR increase. Adipose tissue in 
the intra-abdominal region tends to increasingly accrete, 
according to BMI and WHR, in peri- and post-menopausal 
women compared to those still pre-menopause, due to 
the decline of oestrogen and relative free testosterone 
excess after menopause. Reported recently to be an ac-
tive endocrine organ, visceral adipose tissues closely 
correlate with the pathogenesis of IR by secreting diverse 
cytokines such as leptin, TNF-a and inhibin [21]. Despite 
being most commonly used for assessing IR, HOMA-IR, 
lacking variations due to a significantly greater biological 
variability in individuals, will not be likely to reflect the 
minor change of insulin sensitivity in healthy individuals 
[22, 23]. Considering its low biological variability during 
follicle phase, SHBG concentration was more reliable for 
evaluating IR change caused by treatment or body mass 
in a specific individual [22]. 
SHBG has been reported to increase along with 
ageing in the male population [24], while conflicting 
results have been revealed among women in terms of 
the relationship between SHBG and age. According to 
a recent study by Maggio [9], serum SHBG levels showed 
an age-related U-shaped trajectory, declining from the 
age of 20 to approximately 60 and then progressively 
increasing at older ages. Conversely, in a population of 
1,423 Australian women aged 18–75 Davison et al. [25] 
found that SHBG increased slightly, though signifi-
cantly, with age. In addition, other studies recruiting 
Table III. ROC analysis of SHBG profile for diagnosis of IR in three groups
Tabela III. Analiza ROC profilu stężeń SHBG w diagnostyce insulinooporności w trzech badanych grupach
Groups ROC Standard error P 95% confidence interval
—————————————————-
Lower limit                  Upper limit
Pre-menopause 0.509 0.053 0.878 0.405 0.613
Peri-menopause 0.816 0.092 0.002 0.636 0.996
Post-menopause 0.654 0.071 0.059 0.516 0.793
Figure 1. Receiver operating characteristic (ROC) curves giving 
the diagnostic value of SHBG for predicting IR in peri-menopausal 
women
Rycina 1. Krzywe ROC przedstawiające wartość diagnostyczną 
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small samples of peri-menopausal women showed 
either a decline or no substantial age-related changes 
in SHBG levels [26, 27]. 
In our study, SHBG was found to be significantly 
positively correlated with age only in pre-menopausal 
women, while, independent of age, SHBG significantly 
increased from onset of menopause transition, and slightly 
declined after menopause. SHBG has been demonstrated 
to vary in a single menstrual cycle, showing stable in 
follicular phase and highest in luteal phase [28]. Hence, 
the conflicting results shown above might be relevant to 
the cyclic fluctuation of female steroids and the time of 
investigation in different menstruation phases. 
It is worth noting in this study that after adjustment 
for age and BMI, HOMA-IR in peri-menopausal women 
was closely related only to SHBG. Afterwards, in multiple 
linear regression analysis, SHBG level was found to be the 
only independent significant determinant of HOMA-IR. 
To the best of our knowledge, this would be the first study 
to investigate the possibility of SHBG as a predictor for 
insulin resistance. To define the best discriminating pa-
rameter between insulin tolerance and insulin resistance, 
ROC curves, a method often used to investigate such an 
issue, were calculated and analysed in our study. There 
was no difference regarding HOMA-IR in our cohort in 
different ages. Hence, subjects were defined as having IR 
if they were above the 95th percentile of HOMA-IR when 
all participants were considered as a whole. The AUC of 
SHBG reached a value of 0.816 (0.636~0.996, 95% confi-
dence interval, p = 0.002). With the best cut-off value of 
41.73 nmol/L, the serum SHBG level had a specificity of 
81.4% and a sensitivity of 87.5%. 
The strengths of our study lie in the large sample of 
participants and well-established criteria for identifying 
their menopausal status. 
However, despite our findings, it is important to 
point out that the cross-sectional nature of our study 
limits conclusions about the temporal relation of SHBG 
and IR. In addition, though a simple and commonly 
used marker, HOMA-IR cannot be put on a par with 
the hyperglycaemic-euglycaemic clamp test, known as 
the golden criterion of IR. 
Conclusions
The results of this study indicate that low SHBG level may 
be an independent risk factor of insulin resistance in women 
within the peri-menopause. SHBG is valuable in the predic-
tion of insulin resistance during this particular period.
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